← All trials
NCT07030426
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2025
- Primary completion
- Sep 30, 2027
- Completion date
- Sep 30, 2029
- First posted
- Jun 22, 2025
- Last posted
- Jun 26, 2025
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Queen's University, BelfastLead sponsor
- Queen's University, BelfastSponsor investigator
- Queen's University, BelfastOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.